.Pharmacolibrary.Drugs.C_CardiovascularSystem.C10B_LipidModifyingAgentsCombinations.C10BA07_RosuvastatinAndOmega3Fat.RosuvastatinAndOmega3Fat .Pharmacolibrary.Drugs.C_CardiovascularSystem.C10B_LipidModifyingAgentsCombinations.C10BA07_RosuvastatinAndOmega3Fat.RosuvastatinAndOmega3Fat| name: | RosuvastatinAndOmega3FattyAcids |
| ATC code: | C10BA07 | route: | oral |
| n-compartments | 1 |
Rosuvastatin and omega-3 fatty acids is a fixed-dose combination used for the treatment of dyslipidemia, particularly in patients who require lowering of LDL cholesterol and triglycerides simultaneously. Rosuvastatin is a statin that inhibits HMG-CoA reductase, effectively reducing cholesterol biosynthesis, while omega-3 fatty acids (EPA/DHA) reduce triglyceride levels. The combination may enhance lipid profile improvements compared to monotherapy. The drug is approved and used in several countries for the management of mixed dyslipidemia or hypertriglyceridemia.
There are no published population pharmacokinetic (PK) studies on the fixed combination of rosuvastatin and omega-3 fatty acids (C10BA07). Pharmacokinetic parameters are estimated based on published data for rosuvastatin 10 mg oral (single dose) and omega-3 acid ethyl esters (approx. 1000 mg EPA+DHA) in healthy adults. Parameters represent healthy adult population.